Dogwood Therapeutics (DWTX) Other Non Operating Income (2020 - 2026)
Dogwood Therapeutics (DWTX) posted quarterly Other Non Operating Income of -$5860.0 for Q1 2026, up 99.9% year-over-year from -$2931.4 in Q1 2025, and down 109.29% quarter-over-quarter from $63073.0 in Q3 2025.
Dogwood Therapeutics (DWTX) Other Non Operating Income (2020 - 2026) Analysis & Trends
Dogwood Therapeutics (DWTX) has reported Other Non Operating Income for 7 consecutive years, with -$5860.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Non Operating Income rose 99.9% year-over-year to -$5860.0; the TTM figure through Mar 2026 stood at $61745.0 (up 101.0% YoY), while the FY2025 annual figure was -$6.1 million, down 19824.38% from the prior year.
- Other Non Operating Income slipped to -$5860.0 in Q1 2026 per DWTX's latest filing, from $63073.0 in the prior quarter.
- Across five years, Other Non Operating Income topped out at $63073.0 in Q3 2025 and bottomed at -$6.1 million in Q1 2025.
- Historically, Other Non Operating Income has averaged -$367798.9 across 5 years, with a median of $20239.5 in 2024.
- Annual changes were most pronounced in 2023 — Other Non Operating Income jumped 4361.7% — and 2025, when it plunged 27044.22%.
- Dogwood Therapeutics' Other Non Operating Income stood at $45160.0 in 2022, then declined by 22.6% to $34953.0 in 2023, then sank by 369.02% to -$94032.0 in 2024, then soared by 167.08% to $63073.0 in 2025, then sank by 109.29% to -$5860.0 in 2026.
- Business Quant data shows DWTX's Other Non Operating Income at -$5860.0 in Q1 2026, $63073.0 in Q3 2025, and $4532.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Dogwood Therapeutics | 84.98 Mn | 84.98 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -5,860.00 |
| Sep 30, 2025 | 63,073.00 |
| Jun 30, 2025 | 4,532.00 |
| Mar 31, 2025 | -6.13 Mn |
| Dec 31, 2024 | -94,032.00 |
| Sep 30, 2024 | 20,488.00 |
| Jun 30, 2024 | 19,991.00 |
| Mar 31, 2024 | 22,766.00 |
| Dec 31, 2023 | 34,953.00 |
| Sep 30, 2023 | 39,215.00 |
| Jun 30, 2023 | 36,313.00 |
| Mar 31, 2023 | 40,423.00 |
| Dec 31, 2022 | 45,160.00 |
| Sep 30, 2022 | 16,605.00 |
| Jun 30, 2022 | 4,804.00 |
| Mar 31, 2022 | 906.00 |
| Dec 31, 2021 | -323,733.00 |
| Sep 30, 2021 | 1,509.00 |
| Jun 30, 2021 | 1,495.00 |
| Mar 31, 2021 | 1,400.00 |